回复：恩格列净除增强心肌能量代谢外的益处？ - Suppr | 超能文献

Reply: Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?

作者信息

Santos-Gallego Carlos G, Garcia-Ropero Alvaro, Badimon Juan

出版信息

J Am Coll Cardiol. 2019 Aug 13;74(6):826. doi: 10.1016/j.jacc.2019.06.017.

DOI:10.1016/j.jacc.2019.06.017

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Reply: Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?回复：恩格列净除增强心肌能量代谢外的益处？

J Am Coll Cardiol. 2019 Aug 13;74(6):826. doi: 10.1016/j.jacc.2019.06.017.

2

Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?恩格列净除增强心肌能量代谢外的益处？

J Am Coll Cardiol. 2019 Aug 13;74(6):825-826. doi: 10.1016/j.jacc.2019.05.059.

3

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.恩格列净通过增强心肌能量代谢改善非糖尿病心力衰竭的不良左心室重构。

J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056.

4

Empagliflozin directly improves diastolic function in human heart failure.恩格列净直接改善人类心力衰竭患者的舒张功能。

Eur J Heart Fail. 2018 Dec;20(12):1690-1700. doi: 10.1002/ejhf.1328. Epub 2018 Oct 17.

5

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.恩格列净抑制 SGLT2 可减轻糖尿病小鼠心脏的心肌氧化应激和纤维化。

Cardiovasc Diabetol. 2019 Feb 2;18(1):15. doi: 10.1186/s12933-019-0816-2.

6

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?EMPA-TROPISM 试验（ATRU-4）的原理和设计：恩格列净的“心脏获益”是否与其降血糖活性无关？

Cardiovasc Drugs Ther. 2019 Feb;33(1):87-95. doi: 10.1007/s10557-018-06850-0.

7

Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection?恩格列净引起的心外膜脂肪变化：心肌保护的核心因素？

JACC Heart Fail. 2021 Aug;9(8):590-593. doi: 10.1016/j.jchf.2021.05.006.

8

Diuretics and empagliflozin use: authors' reply.

Emergencias. 2018;30(4):279-280.

9

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.恩格列净可减轻链脲佐菌素诱导的糖尿病大鼠心肌钠钙失调并逆转心脏重构。

Int J Mol Sci. 2019 Apr 4;20(7):1680. doi: 10.3390/ijms20071680.

10

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.恩格列净，一种 SGLT2 抑制剂，通过改变糖尿病大鼠心脏代谢组和抗氧化剂来降低急性心肌梗死后的死亡率。

J Pharmacol Exp Ther. 2019 Mar;368(3):524-534. doi: 10.1124/jpet.118.253666. Epub 2018 Dec 14.

引用本文的文献

1

Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond.老年心力衰竭患者2型糖尿病的药物治疗：随机试验及其他研究

Heart Fail Rev. 2023 May;28(3):667-681. doi: 10.1007/s10741-021-10182-x. Epub 2021 Dec 2.

2

Mitochondrial Mechanisms in Diabetic Cardiomyopathy.糖尿病心肌病中的线粒体机制。

Diabetes Metab J. 2020 Feb;44(1):33-53. doi: 10.4093/dmj.2019.0185.